Antitumor effect of a pyrazolone-based complex [Cu(PMPP-SAL)(EtOH)] against murine melanoma B16 cell in vitro and in vivo by AYIPAIRI ABULA et al.
561
Acta Pharm. 70 (2020) 561–575 Short communication
https://doi.org/10.2478/acph-2020-0040
Antitumor effect of a pyrazolone-based complex 
[Cu(PMPP-SAL)(EtOH)] against murine melanoma 
B16 cell in vitro and in vivo
Pyrazolone-based derivative metal complexes were reported 
to have cytotoxicity in some tumor cells. In this study, 
the antitumor effect of [Cu(PMPP-SAL)(EtOH)] (PMPP-SAL 
= N-(1-phenyl-3-methyl-4-propenylidene-5-pyrazolone)-
salicylidene hydrazide anion) in murine melanoma B16 
cells in vitro and in vivo was investigated. The results showed 
that [Cu(PMPP-SAL)(EtOH)] inhibited the survival of B16 
cells in vitro, and the IC50 value was superior to cisplatin 
(DDP) (p < 0.001). B16 cell apoptosis was significantly higher 
in comparison to the control group (DMSO) (p < 0.01), 
and cell cycle arrest occurred at the G0/G1 phase. When 
challenged C57 BL/6J mice were treated with [Cu(PMPP-
SAL)(EtOH)], a smaller volume of B16 solid tumors were 
reported than the control group (p < 0.01), with lower posi-
tive expression indices of CD 34, vascular endothelial 
growth factor (VEGF) and basic fibroblast growth factor 
(bFGF) (p < 0.01). Moreover, the tumor growth was sup-
pressed in mice due to the induction of apoptosis, as de-
tected by the TUNEL assay (p < 0.001). In summary, 
[Cu(PMPP-SAL)(EtOH)] effectively inhibited the growth of 
B16 cells in vitro and in vivo due to the induction of apopto-
sis and the inhibition of intra-tumoral angiogenesis, demon-
strating its therapeutic potential in melanoma treatment.
Keywords: malignant melanoma, [Cu(PMPP-SAL)(EtOH)], 
apoptosis, tumor microangiogenesis
Malignant melanoma is the most invasive and highly metastatic skin cancer (1, 2), 
demonstrating in vivo a natural apoptosis rate lower than other types of tumors. Melanoma 
accounts for only 5 % of all skin cancers. However, about 80 % of all skin cancer-related 
deaths are attributed to melanoma (3), posing a serious threat to human health. Although 
cisplatin (DDP) can be used as single-agent chemotherapy in metastatic melanoma (4), it 
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acquired resistance (5, 6). In addition, due to the strong drug resistance observed in mela-
noma cells (7), there is an urgent need to develop more effective anti-melanoma drugs.
Non-platinum metal-containing chemotherapeutic drugs have been characterized by 
high activity, low toxicity, and good antitumor effects (8–10). Recent studies have shown 
that the complexes formed by double Schiff’s bases and copper are capable of inhibiting 
tumor growth and prolonging the survival time of tumor-bearing animals, eliminating 
the toxic side effects and drug resistance observed with traditional drugs such as DDP (11, 
12, 14). Pyrazolone complexes, within the category of double Schiff base complexes, can 
form several types of complexes by reacting with different metals. Notably, pyrazolone-
based metal complexes possess the advantages of simple synthesis, stable properties, easy 
structural modification, and obvious antitumor effects (8–10) and are expected to develop 
as a new type of anticancer drugs.
Recent studies have implied that the pyrazolone-based derivative complex [Cu(L1)
(μ-Cl)]Cl (L1=3-methyl-5-oxo-1-phenyl-3-pyrazoline-4-carboxaldehyde) had a significantly 
lower IC50 value in melanoma B16 cells than DDP. In addition, this complex displayed 
significant cytotoxicity in B16 cells compared to DDP (12). Some studies suggest that the 
pyrazolone copper complex [Cu(R-L2)2]·EtOAc and [Cu(S-L2)2]·EtOAc (R/S-HL2 = (R/S)-(1-
naththyl)-3-methoxysalicylaldimine, EtOAc = ethyl acetate)) had demonstrated obvious 
cytotoxic effects on breast cancer MDA-MB-231 cells, lung cancer A549 cells, and cervical 
cancer HeLa cells. Furthermore, the above complexes induce apoptosis and necrosis in 
MDA-MB-231 cells (13). However, there are limited reports available on the antitumor 
 effects of the pyrazolone-based derivative copper complex in melanoma.
Previously, cytotoxicity and cell apoptosis induced by pyrazolone-based derivative 
copper complex Lgf-YL-9 ([Cu(PMPP-SAL)(EtOH)] (PMPP-SAL = 1-phenyl-3-methyl-4-pro-
pionyl-5-pyrazolone and salicylic hydrazide)) on human mouth floor cancer KB cells and 
multidrug-resistant KBV200 cells were investigated. The results indicated potent cyto-
toxicity against KB and KBV200 cells and induced cell apoptosis (14). Meanwhile, our pre-
vious study on the acute toxicity of [Cu(PMPP-SAL)(EtOH)] showed that [Cu(PMPP-SAL)
(EtOH)] at low concentration had mild toxicity in mice, with lower acute toxicity than DDP 
(15). In this study, we have examined the anti-proliferative effect of [Cu(PMPP-SAL)(EtOH)] 
in murine melanoma B16 cells, and the in vivo effect on angiogenesis in B16 solid tumor. 
The results of the present study would provide insight into the application of pyrazolone-
based derivatives in the treatment of melanoma.
EXPERIMENTAL
Materials
3-(4,5-Dimetrylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma, USA). 
Apoptosis detection kit and cell cycle kit were purchased from Lianke. Dimethyl sulfoxide 
(DMSO, Sigma), Hoechst 33258. Other routine laboratory reagents were obtained from 
commercial sources of analytical grade. Neofuge 13R High-Speed Centrifuge (Heal Force, 
Hong Kong, China). Benchmark plus Microplate Reader (Bio-Rad, USA). XD-101 Invert 
Microscope (Jiangnan Brand) (Wuhan Oka Technology Co., Ltd.). 3423 Type CO2 incubator 
(Themo Corporation, USA). Flow Cytometry (US BD). In situ cell apoptosis detection kit 
was purchased from Wuhan Boster Biological Technology, China.
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Complex and animals
The pyrazolone-based derivative copper complex [Cu(PMPP-SAL)(EtOH)] was pre-
pared and characterized with the purity of > 95 % by the Institute of Applied Chemistry, 
Xinjiang University (Fig. 1) (16). C57BL/6J female mice (18–22 g) were purchased from the 
Laboratory Animal Center of Xinjiang Medical University. The animal experimental pro-
tocol was approved by the Animal Ethics Committee of Xinjiang University (license num-
ber: SCXK (new) 2016-0003).
Fig. 1. Chemical structure of [Cu(PMPP-SAL)(EtOH)].
Cell lines and culture
The murine melanoma cell lines (B16) and non-tumor rat Schwann (RSC) cells were 
obtained from the Xinjiang Key Laboratory of Biological Resources and Genetic Engineer-
ing. The cells were cultured in RPMI 1640 medium (HyClone, Thermo) containing 10 % 
fetal bovine serum (FBS, Gibco) and 1 % penicillin-streptomycin (100 U mL–1 penicillin and 
100 μg mL–1 streptomycin) under humidified 5 % CO2 (3423 Type CO2 incubator, Thermo 
Corporation, USA) atmosphere at 37 °C as previously described (17).
Cell viability assay
B16 and RSC cells were seeded in 96-well plates at densities of 5 × 104 and 2.5 × 104 cells, 
respectively. After 24 h of incubation, the cells were treated with various concentrations of 
[Cu(PMPP-SAL)(EtOH)] (1, 5, 10, 15 μmol L–1) and the control, dimethyl sulfoxide (DMSO) 
(Sigma, USA) (0.1 % in culture media). After 24, 48 and 72 h of treatments, 20 μL of MTT 
(Sigma, USA) (10 μmol L–1 MTT in phosphate-buffered saline (PBS) was added and cells 
were incubated for a further 4 h. The supernatant was removed and MTT crystals were 
dissolved using 100 μL of anhydrous DMSO in each well. Next, the absorbance was read 
at 570/655 nm using the Benchmark plus Microplate Reader (Bio-Rad, USA). The percent-
age of cell growth inhibition was calculated using the Eqation 1:
 Cell growth inhibition (%) = (1 – mean exp. abs./mean control abs.) × 100 % (1)
The IC50 value was determined. All experiments were repeated at least three times.
Wound healing assay
The cells were plated at 5 × 104 cells with 2 mL per well in 6-well plates, and cultured to 
full confluence, with monolayers forming overnight after incubation. Next, a 10 μL sterile 
pipette tip was used to create a straight wound in each cell layer. Next, the cells were washed 
three times with PBS and incubated with different concentrations of [Cu(PMPP-SAL)(EtOH)] 
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(5, 10, 15M) in serum-free medium for 24 h. The gap created by the scratch was observed at 
0, 12, 24 h of incubation and photographed under XD-101 Invert Microscope (Jiangnan, 
 China) at 200 × magnification.
Cell colony-forming assay
The cells were plated at 1 × 103 cells with 2 mL per well in 6-well plates. After overnight 
incubation, the cells were treated with various concentrations of [Cu(PMPP-SAL)(EtOH)] 
(5, 10, 15M) for 24 h, and washed with ice-cold PBS three times, and then cultured in 10 % 
1640 medium for 4 d. After more than 20 colonies being formed, the cells were fixed with 
1 mL of 4 % paraformaldehyde solution for 20 min and then stained with 0.1 % crystal violet 
solution (95 % anhydrous ethanol + 5 % PBS) for 15–20 min.
Hoechst 33258 staining
A sterile clean coverslip was placed in 6-well plates and B16 cells were seeded at a 
density of 5 × 104 cells with 2 mL per well. After treatment with various concentrations of 
[Cu(PMPP-SAL)(EtOH)] (5, 10, 15M), B16 cells were washed with ice-cold PBS twice and 
stained with 1 mL Hoechst 33258 (Sigma, USA) in the dark at 37 °C for 5 min (final concen-
tration, 0.5 μg mL–1). After washing with PBS, the cells were observed using fluorescence 
microscopy (Leica Dmirb, Germany) in random microscopic fields at 400 × magnification 
(18).
Cell cycle assay
B16 cells were seeded in 6-well plates at 5 × 104 cells with 2 mL per well, treated with 
different concentrations of [Cu(PMPP-SAL)(EtOH)] (5, 10, 15M) and DMSO (control), and 
then incubated for 24 h and 36 h at 37 °C/5 % CO2 in humidified atmosphere. The cells then 
were collected by centrifugation at 1000 × g for 2 min (Neofuge 13R High-Speed Centri-
fuge, Heal Force, Hong Kong, China). Next, the cells were fixed by the dropwise addition 
of an equivalent volume of cold 70 % ethanol after washed twice with cold PBS. The sam-
ples were stored at –20 °C. The cells were pelleted and then resuspended in propidium 
iodide/RNase PBS solution and analyzed using the FACS Calibur flow cytometer (US, BD).
Annexin V/PI double staining assay
Cell apoptosis was detected by annexin V staining. Briefly, B16 cells were treated with 
[Cu(PMPP-SAL)(EtOH)] (5, 10, 15 mol L–1) and washed twice with PBS. Next, the cells were 
then suspended in 400 μL Binding buffer and treated with annexin V and propidium io-
dide (PI) staining. After 24 and 36 h of incubation, the cells were sorted and analyzed by 
flow cyto metry.
Establishment of the tumor-bearing model in mice
B16 cells were suspended in normal saline at a density of 1 × 106 cells and implanted 
in C57BL/6J mice (6 weeks old) for chemotherapeutic studies. The mice were treated sub-
cutaneously with 2 × 105 cells under the right hind leg (dorsum). Twenty-four hours after 
565
A. Abula et al.: E Antitumor effect of a pyrazolone-based complex [Cu(PMPP-SAL)(EtOH)] against murine melanoma B16 cell in vitro and 
in vivo, Acta Pharm. 70 (2020) 561–575.
 
inoculation, the animals were randomized into 5 groups (7 mice per group) including 
control (DMSO, 10 μmol L–1), positive control group (DDP, 20 μmol L–1) and [Cu(PMPP-
SAL)(EtOH)] (20, 40, 60 μmol L–1).
Effect of [Cu(PMPP-SAL)(EtOH)] on the B16 solid tumor growth
Five days after injection, when the tumor reached 0.3 × 0.3 cm in size, the drug was 
intratumorally injected at a volume of 100 μL per mice for 8 days. The volume of the tumor 
was measured every 2 days with calipers, with the longest (a) and the shortest diameter (b) 
of the tumor were measured. Tumor volumes (V) and relative tumor volume (RV) were 
calculated using the Equation 2.
 V = a × b2 × 0.5, RTV = V/V0 (2)
where V0 is the tumor volume before dosing and V is the tumor volume after dosing (19). 
On the day after the drug was stopped, the mice were sacrificed. B16 tumors were excised 
and weighed.
Immunohistochemical analysis
Tumor tissues obtained from mice were fixed in 10 % formaldehyde solution in phos-
phate buffer and routinely processed by paraffin embedding. The changes in the tissue 
were observed under light microscopy after hematoxylin-eosin (HE) staining. After de-
waxing the tumor paraffin sections of each group of mice, the sections were incubated 
with rabbit anti-CD34, vascular endothelial growth factor (VEGF), and basic fibroblast 
growth factor (bFGF) mAb at 4 °C overnight, and color development carried out by immer-
sion in 0.05 % 3,3’-diamino-benzidine tetrahydrochloride (DAB) as chromogen for 5 min. 
The distribution of CD 34, VEGF, and bFGF in the tumor was observed using microscopy. 
In accordance with the SV-0002 two-step immunohistochemistry kit manufacturer’s in-
struction, the results of the brown and the intensity of the color were taken as an indicator 
of observation. First, the distribution of CD 34, VEGF or bFGF on the whole pathological 
tissue section was observed under a low power microscope (100×) and the most intensive 
5 regions, “hot spots” of CD 34, VEGF and bFGF, were identified. The number of CD 34, 
VEGF, and bFGF in each spot was counted using a high power microscope (200×), and the 
average number of cells in the five hot spots is taken as the density of CD 34, VEGF or bFGF 
in the tumor of the mice.
TUNEL apoptosis assay in vivo
Apoptosis analysis was performed by TUNEL (terminal deoxynucleotide transferase-
mediated dUTP nick end-labeling) staining using an in situ cell apoptosis detection kit 
(Boster Biological Technology, Wuhan, Hubei, China) according to the manufacturer’s in-
structions. The results of the bluish-violet were taken as an indicator of apoptotic cells. TU-
NEL-positive nuclei, a pyknotic nucleus with bluish-violet granules, were visualized and 
analyzed under a light microscope (200×). Cell numbers were counted in 5 random fields and 
apoptosis indexes (AI) were calculated as the ratio of the positive cell number to the total 
tumor cell number, based on the mean value from five high power fields via computer- 
- assisted assay.
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RESULTS AND DISCUSSION
Synthesis of the copper complex [Cu(PMPP-SAL)(EtOH)](16)
The elemental analysis, single-crystal X-ray diffraction, and thermogravimetric 
 analysis of [Cu(PMPP-SAL)(EtOH)] were performed (16), the results indicated that the 
 complex [Cu(PMPP-SAL)(EtOH)] was a pure substance.
[Cu(PMPP-SAL)(EtOH)] effectively inhibited the growth of B16 cells in vitro
Melanoma is a type of skin tumor characterized by a high degree of malignancy, 
multiple occurrences and extremely low survival rate of patients. It has been well docu-
mented that this type of neoplasm presents a high metastatic rate, and is able to involve 
Fig. 2. The inhibitory effect of [Cu(PMPP-SAL)(EtOH)] on the proliferation of B16 cells: a) B16 cells were 
treated with indicated concentrations of [Cu(PMPP-SAL)(EtOH)] for 24, 48 and 72 h, respectively, and 
cell viability was measured by MTT assay; b) IC50 values of [Cu(PMPP-SAL)(EtOH)] and positive control 
group (DDP) in B16 and RSC cells after 72 h treatments. ***p < 0.001 vs. positive control group (DDP); c) 
the colony formation in B16 cells, B16 cells were treated with indicated concentrations of [Cu(PMPP-
SAL)(EtOH)] for 24 h, then incubated for 5 d. Then the cells were fixed with methanol and stained with 
crystal violet. d) The corresponding cell healing rate was calculated. Data are presented as mean ± SD 
(n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 vs. control group (DMSO, 0.1 % in culture media).
a)                                                                   b)
c)                                                                   d)
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nearly every tissue (20). Currently, effective therapeutic methods for the treatment of mela-
noma remain poorly investigated. Therefore, the development of new treatment methods 
and drugs is of crucial medical significance for treating melanoma and improving the 
survival rate in patients.
Here, to assess the growth inhibition in B16 cells induced by [Cu(PMPP-SAL)(EtOH)] 
complex, the MTT assay was performed after 24, 48, 72 h of drug treatment. The results 
indicated that [Cu(PMPP-SAL)(EtOH)] inhibited B16 cell proliferation in a concentration- 
and time-dependent manner (Fig. 2a). After 72 h drug treatment, the IC50 value of 
[Cu(PMPP-SAL)(EtOH)] in B16 cells was 8.5 μmol L–1, which was markedly effective than 
DDP (IC50: 30.1 μmol L–1) in inhibiting B16 cell growth (p < 0.05). The IC50 value of [Cu(PMPP-
SAL)(EtOH)] for non-neoplastic RSC cells was similar to DDP (Fig. 2b). These results sug-
gested that [Cu(PMPP-SAL)(EtOH)] had a relatively strong cytotoxic profile in cancer cells 
compared to normal cells (p < 0.05).
To investigate the effect of [Cu(PMPP-SAL)(EtOH)] on colony formation in B16 cells, 
we examined the growth capacity of B16 cells at a very low density. The results indicated 
that [Cu(PMPP-SAL)(EtOH)] had a significant toxic effect on the growth of B16 cells (Fig. 
2c), inhibiting colony formation in B16 cells in a concentration-dependent manner (Fig. 2d). 
The cells in the treatment groups demonstrated a significant reduction in colony-forming 
efficiency compared to the blank control group, indicating that [Cu(PMPP-SAL)(EtOH)] 
inhibited the growth of B16 cells (p < 0.01).
[Cu(PMPP-SAL)(EtOH)] inhibited the migration of B16 cells
Metastasis is one of the main features of malignant melanoma. To examine the effect 
of [Cu(PMPP-SAL)(EtOH)] on B16 cell migration, we performed cell healing assays in vitro. 
Fig. 3. Wound healing assay of B16 cells 24 h after treatment with [Cu(PMPP-SAL)(EtOH)]: a) B16 cells 
were treated with indicated concentrations of [Cu(PMPP-SAL)(EtOH)] and migration was observed 
under a microscope at 200 × magnification; b) the corresponding cell healing rates were calculated. 
*p < 0.05, **p < 0.01, ***p < 0.001 vs. control group (DMSO, 0.1 % in culture media).
a)                                                                                             b)
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Cell migration was observed using an inverted microscope. The results demonstrated that 
the number of migrating [Cu(PMPP-SAL)(EtOH)]-treated cells was lower than that in the 
control group (Fig. 3a). Hence, [Cu(PMPP-SAL)(EtOH)] inhibited the migration of B16 cells 
in a concentration- and time-dependent manner. The cell wound healing rate at 24 h in the 
15 μmol L–1 treatment group was significantly lower (5.42 ± 0.22 %) compared to the control 
group (77.79 ± 7.35 %) (p < 0.001) (Fig. 3b).
[Cu(PMPP-SAL)(EtOH)] affected the morphology of B16 cells
The inhibition of cell growth in tumor cells is usually associated with increased apop-
tosis (21). To detect whether [Cu(PMPP-SAL)(EtOH)] can induce apoptosis in the tumor cells, 
B16 cells were stained by Hoechst 33258 with various concentrations of [Cu(PMPP-SAL)
(EtOH)] for 24 h and observed using inverted phase-contrast microscopy. As shown in Fig. 
4, compared to the control group, the 15 μmol L–1 treated group revealed a reduction of ad-
herent cell numbers and the presence of small and round cells, bright blue nuclei due to 
karyopyknosis and chromatin condensation (Fig. 4). The results indicated the existence of 
induced-apoptosis attributed to [Cu(PMPP-SAL)(EtOH)] treatment. Furthermore, cell death 
induced by [Cu(PMPP-SAL)(EtOH)] might be associated with the induction of apoptosis.
[Cu(PMPP-SAL)(EtOH)] arrested the cell cycle of B16 cells
To detect the effect of [Cu(PMPP-SAL)(EtOH)] on cell cycle distribution, after treat-
ment with different concentrations of [Cu(PMPP-SAL)(EtOH)] for 24 h and 36 h, the cell 
cycle distribution of B16 cells was measured using flow cytometry. The rate of PI-stained 
positive cells in the G0/G1 phase was significantly increased after 24 h (63.11 ± 1.02 %) and 
36 h (71.53 ± 0.38 %) of treatment, respectively (Fig. 5, 4a). The results indicated that [Cu(PMPP-
SAL)(EtOH)] arrested B16 cells at the G0/G1 phase of the cell cycle in a time- and dose-
dependent manner (p < 0.05) (Fig. 5b).
Fig. 4. B16 cell apoptosis induced by [Cu(PMPP-SAL)(EtOH)]. B16 cells were treated with various con-
centrations of [Cu(PMPP-SAL)(EtOH)] for 24 h and stained with Hoechst 33258. Samples were observed 
under a fluorescent microscope at 400× magnification. The red arrow point to the apoptotic bodies.
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[Cu(PMPP-SAL)(EtOH)] induced early apoptosis of B16 cells
Annexin V/PI double staining is a sensitive method to detect apoptosis. To detect 
early apoptosis in B16 cells treated with [Cu(PMPP-SAL)(EtOH)], Annexin V/PI double 
staining was performed. As shown in Fig. 6a,b, after treatment for 24 h and 36 h, the num-
ber of apoptotic cells treated with [Cu(PMPP-SAL)(EtOH)] increased remarkably in a time- 
and dose-dependent manner (2.02 ± 0.69 % to 8.24 ± 0.51 %), and was significantly higher 
compared to the control group (p < 0.01) (Fig. 6b).
[Cu(PMPP-SAL)(EtOH)] effectively inhibited the growth of B16 cells in vivo
Currently, there are limited reports on the in vivo antitumor activity of pyrazolone metal 
complexes. In the present study, C57 BL/6J treated with [Cu(PMPP-SAL)(EtOH)] demonstrated 
a significantly lower RV (V/V0) in comparison to the control group (p < 0.01) (Fig. 7a, Table I). 
The relative curves of tumor growth and the tumor size are shown in Fig. 7.
In addition, the tumor inhibition rates were significantly increased after treatment with 
different concentrations of [Cu(PMPP-SAL)(EtOH)] (p < 0.01) (Table I), indicating that 
[Cu(PMPP-SAL)(EtOH)] exerted a strong inhibitory effect on B16 solid tumor formation in C57 
BL/6J mice. Notably, [Cu(PMPP-SAL)(EtOH)] did not cause any death or induce weight loss in 
Fig. 5. Cell cycle changes in B16 cells after [Cu(PMPP-SAL)(EtOH)] treatment by flow cytometry: a) B16 
cells were treated with indicated concentrations of [Cu(PMPP-SAL)(EtOH)] for 24 h, 36 h, respectively; 
b) then subjected to cell cycle analysis after PI staining. Data are presented as mean ± SD (n = 3). *p < 0.05 
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Fig. 6. Annexin V-FITC/PI staining detected apoptosis in B16 cells after treatment with [Cu(PMPP-SAL)
(EtOH)] for 24 h, 36 h with indicated concentrations: a) B16 early apoptotic cells were analyzed by FACS 
Calibur flow cytometer; b) summary data (mean ± SD) of early apoptotic cells are shown (n = 3). *p < 0.05, 
**p < 0.01 vs. control group (DMSO, 0.1 % in culture media). 











10 μmol L–1 
19.50 ± 0.97 21.6 ± 0.72 1.30 ± 0.26 0.00
[Cu(PMPP-SAL)(EtOH)]
20 μmol L–1 17.88 ± 0.94 19.6 ± 0.30 0.84 ± 0.39 35.58 *
40 μmol L–1 18.4 ± 1.22 18.9 ± 1.51 0.72 ± 0.16 44.44 **
60 μmol L–1 17.28 ± 0.51 17.75 ± 0.86 0.59 ± 0.07 54.8 **
Cisplatin (DDP) 
20 μmol L–1
18.49 ± 0.84 19.05 ± 1.32 0.73 ± 0.09 44.06 **
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our experimental system (Table I). These data suggested that the toxicity of [Cu(PMPP-SAL)
(EtOH)] was tolerable. Therefore, we determined that [Cu(PMPP-SAL)(EtOH)] induced less 
damage in the melanoma-bearing mice, with lower toxic side effects. This is consistent with 
the acute toxicity of [Cu(PMPP-SAL)(EtOH)] in mice as shown in the previous study (15).
Tissue section and tumor immunohistochemistry analysis
Researchers have proposed that the inhibition of the tumor angiogenesis might cause 
hypoxia in tumor cells and reduce the nutrient supply to tumor cells, eventually leading 
to tumor cell apoptosis and thus inhibiting tumor growth (22). The expression of VEGF 
and bFGF could affect the formation and growth of tumor blood vessels (23). Furthermore, 
newly generated blood vessels not only provide more nutrients to tumors but also increase 
the rate of tumor metastasis. Hence, microvessel density (MVD) is considered a gold stan-
dard for examining the invasion and metastatic potential of many primary tumors. Among 
the markers of vascular endothelial cells, CD34 has the highest sensitivity and hence the 
density of microvessels in tissues can be determined by detecting CD34 expression. CD34 
promotes the proliferation of tumor vascular endothelial cells, as well as the interaction 
Fig. 7. Growth inhibition of B16 cells in C57BL/6J mice after [Cu(PMPP-SAL)(EtOH)] treatment. 
C57BL/6J mice were implanted subcutaneously (s.c.) with 2 × 105 cells under the right hind leg (dor-
sum). Animals were randomized into five groups including control (DMSO, 10 μmol L–1), positive 
control (DDP, 20 μmol L–1) and [Cu(PMPP-SAL)(EtOH)] group (20, 40, 60 μmol L–1). After injection for 
five days, when the tumor 0.3 × 0.3 cm in size, the mice were injected intratumorally with the drug 
volume of 100 μL/mouse for 8 days. The volume of the tumor was measured every 2 days; a) data are 
presented as means ± SD of the tumor volume for each group of 7 experimental animals; b) the picture 
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between malignant tumor growth-related proteins, thereby enhancing the infiltration and 
metastatic ability of malignant tumors (24).
In this regard, to further investigate the effect of [Cu(PMPP-SAL)(EtOH)] on angiogenesis, 
we examined its potential regulatory effect on the expression of angiogenic proteins CD34, 
VEGF, and bFGF. The MVD values in the drug treatment group were significantly lower 
than those in the DMSO control group (p < 0.001) (Table II).
Immunohistochemical results also showed that the cell densities of VEGF and bFGF 
protein in untreated tumor-bearing mice were highly elevated, whereas these two indexes 
were also decreased significantly in tumor-bearing mice received [Cu(PMPP-SAL)(EtOH)] 
treatment at three doses (20, 40 and 60 μmol L–1) with lighter staining when compared to 
the negative control (Fig. 8), the 40, 60 μmol L–1 dose groups demonstrated significantly 
lower expression of VEGF and bFGF than the control group (Table II) (p < 0.01), which sug-
gests that higher concentrations of [Cu(PMPP-SAL)(EtOH)] could inhibit the formation of 
tumor microvessels by inhibiting the expression of CD34, VEGF, and bFGF, leading to tu-
mor growth inhibition through tumor cell apoptosis.
Table II. Cell density expression of MVD, VEGF, bFGF in tumor tissues of C57 BL/6J mice
Groups MVD VEGF bFGF
Negative Control 
10 μmol L–1 113 ± 19.56*** 110 ± 19.17*** 109.2 ± 20.59***
[Cu(PMPP-SAL)(EtOH)] 20 μmol L–1 57.4 ± 8.20** 56.4 ± 7.57** 58 ± 5.39**
40 μmol L–1 33.2 ± 7.79 35.6 ± 8.01 37.5 ± 5.46
60 μmol L–1 22.8 ± 4.92 22.6 ± 5.41 22 ± 2.35
Cisplatin (DDP) 
20 μmol L–1 38 ± 11.73* 34 ± 8.15* 39.8 ± 10.21*
N = 5. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control group.
Fig. 8. Immunohistochemical analysis of CD34, VEGF, and bFGF in tumor tissues. The tumor issues 
derived from C57 BL/6J mice were treated with indicated concentrations of [Cu(PMPP-SAL)(EtOH)], 
positive control group (DDP), and control group (DMSO). The distribution of CD34, VEGF, and bFGF 
on the whole pathological tissue section was observed under a microscope at 200× magnification.
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[Cu(PMPP-SAL)(EtOH)] increased the number of apoptotic cells in vivo
A small number of apoptotic cells were present in the tumors of the untreated control 
group; however, a large number of bluish violet apoptosis was detected in tumors treated 
with the indicated concentrations of [Cu(PMPP-SAL)(EtOH)] (Fig. 9a). Moreover, [Cu(PMPP-
SAL)(EtOH)] dose-dependently increased the values of AI (p < 0.05 and p < 0.01) (Fig. 9b). 
These results suggested that [Cu(PMPP-SAL)(EtOH)] suppresses tumor growth of B16 
through the induction of apoptosis in vivo. These results are in accordance with those re-
ported by Hua Yao et al (25).
CONCLUSIONS
In conclusion, the present study validated that [Cu(PMPP-SAL)(EtOH)] had indicated 
a good inhibitory effect on murine melanoma in vitro and in vivo. The down-regulation of 
Fig. 9. a) Apoptosis detected using TUNEL assay in C57 BL/6J mice tumor tissues treated with indicated 
concentration of [Cu(PMPP-SAL)(EtOH)], positive control group (DDP), and control group (DMSO). 
TUNEL-positive nuclei, a pyknotic nucleus with indigo granules, were visualized and analyzed under 
a microscope at 200× magnification; b) The apoptosis index in C57 BL/6J mice tumor tissues. Data are 
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CD34, VEGF, and bFGF protein expression in mice could inhibit tumor microangiogenesis 
and ultimately lead to tumor growth inhibition in vivo. Tumor-bearing mice demonstrated 
no serious adverse reactions to [Cu(PMPP-SAL)(EtOH)] treatment, indicating the potential 
of this complex in melanoma treatment. However, melanoma is characterized by high 
drug resistance and high risk for recurrence, and hence it is difficult to obtain a superior 
therapeutic effect only through monotherapy or a single-agent treatment. Therefore, fur-
ther studies need to be designed to investigate the underlying mechanism of apoptosis and 
combine [Cu(PMPP-SAL)(EtOH)] with other chemotherapeutic drugs to enhance their 
therapeutic effect on melanoma tumors.
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